Metagenomi Therapeutics, Inc. MGX
1.15
0.00
0.00%
as of 25 Sep
- Market cap
- $43.4M
- P/E
- 0.0×
Follow MGX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.30 | 2.26 | 2.39 | 2.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.30) | (2.38) | (2.56) | (4.16) | |
P/B ratio |
0.40 | 0.37 | 0.38 | 0.50 | |
Price to Tangible BV |
0.40 | 0.37 | 0.38 | 0.50 | |
EV/Sales |
(3.36) | (2.67) | (2.78) | (2.11) | |
EV/EBITDA |
0.47 | 0.66 | 0.75 | 0.72 | |
EV/Operating CF |
0.53 | 0.68 | 0.79 | 0.71 | |
EV/FCF |
0.53 | 0.68 | 0.78 | 0.71 | |
Quick Ratio |
4.37 | 6.23 | 7.03 | 6.26 | |
Current Ratio |
4.50 | 6.43 | 7.22 | 6.42 | |
Net Debt/EBITDA |
4.46 | 5.92 | 6.83 | 8.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.09 | 0.09 | 0.10 | |
Operating CF/Net income |
0.71 | 0.92 | 1.05 | 1.04 | |
Capex/Depreciation |
(0.07) | (0.03) | (0.10) | (0.15) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
(8,759.53%) | 1,546.47% | 549.76% | 291.99% | |
Selling, General and Administrative Expense of Revenue |
(2,336.19%) | 523.64% | 173.28% | 71.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(882.49%) | 204.49% | 68.88% | 34.76% | |
Graham Net Nets |
1.41 | 1.70 | 1.71 | 1.36 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(209.24%) | (171.64%) | (146.30%) | (101.27%) | |
Free Cash Flow Yield |
(191.45%) | (173.75%) | (148.19%) | (104.39%) | |
Revenue per Share |
(0.01) | 0.03 | 0.11 | 0.23 | |
Operating CF per Share |
(0.52) | (0.56) | (0.63) | (0.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.56) | (0.63) | (0.57) | |
Cash per Share |
3.20 | 3.73 | 4.32 | 4.93 | |
Shareholders Equity per Share |
2.99 | 3.67 | 4.26 | 4.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.99 | 3.67 | 4.26 | 4.78 | |
Free Cash Flow |
(19.64) | (21.20) | (23.63) | (21.33) | |
Working Capital |
96.84 | 122.06 | 142.61 | 160.24 | |
Capital Expenditures |
(0.12) | (0.02) | (0.08) | (0.07) | |
Net Current Asset Value |
63.33 | 85.39 | 103.03 | 120.33 | |
EV/EBIT |
0.45 | 0.64 | 0.73 | 0.71 | |
Capex to Sales |
(0.49) | 0.02 | 0.02 | 0.01 | |
Net Profit Margin |
10,693.39% | (1,847.68%) | (576.02%) | (235.51%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.78 | 0.77 | |
Average Payables |
2.75 | 2.53 | 1.01 | 2.16 | |
Average Assets |
222.99 | 247.41 | 272.85 | 303.14 | |
Average Common Equity |
154.20 | 175.22 | 196.73 | 217.11 |
Columns are period end dates